Key Highlights

● Moderna sank Friday as traders trimmed positions ahead of Phase 3 intismeran data.

● Intismeran is an individualized cancer vaccine Moderna is developing with Merck.

● Goldman Sachs raised its price target to $137 from $120, keeping a Neutral rating.

● A rate-driven biotech selloff coincided with the decline; the 10-year yield eased to roughly 5.1.

Positioning before a big readout

Moderna (NASDAQ:MRNA) sank in Friday's session, finishing among the heaviest decliners on the Nasdaq Composite. According to market reports, traders trimmed positions ahead of Phase 3 data for intismeran, the individualized cancer vaccine Moderna is developing with Merck (NYSE:MRK), due later this month.

Reports differed on the size of the move. Several market reports showed a steep decline, with figures varying depending on the time of day captured.

The trimming followed a remarkable rally. Moderna's shares have multiplied in value this year, according to market reports. One report described Friday's selling as profit-taking ahead of the trial data. After such a run, some traders often choose to reduce exposure before a binary event such as a major trial result, rather than risk a sharp reversal if the data disappoint.

An analyst's cautious target

Goldman Sachs raised its price target on Moderna to $137 from $120 while keeping a Neutral rating, according to market reports. Even after the increase, that target sits well below the stock's recent trading level, implying substantial downside from current prices, according to the reports.

Intismeran is a messenger RNA-based therapy designed to train a patient's immune system to recognize the specific mutations in their own tumor. Moderna is best known for its COVID-19 vaccine, and the cancer program represents one of its most closely watched efforts to broaden its business beyond respiratory vaccines.

Rates weighed on biotech

Moderna's decline also coincided with a rate-driven selloff in biotech and clinical-stage health care names, per market commentary. Higher long-term Treasury yields tend to weigh on companies whose value depends on profits expected years in the future. The 10-year Treasury yield eased to roughly 5.1 at the close, but it topped 5.3 earlier in October, its highest level since 2002.

Market data showed steep declines in Novavax (NASDAQ:NVAX), which fell to about $11.20, and in PacBio (NASDAQ:PACB), which dropped to $1.74. QuidelOrtho (NASDAQ:QDEL), Azenta (NASDAQ:AZTA), Repligen (NASDAQ:RGEN) and Ocular Therapeutix (NASDAQ:OCUL) also fell. The broader health care sector, by contrast, drew defensive buying, with record highs reported for the sector ETF.

A volatile market backdrop

The Nasdaq Composite fell 572.99 points to 26,140.03, closing its worst week since the week ended June 26. The S&P 500 lost 84.62 points to 7,659.44, and the Dow Jones Industrial Average slipped 175.28 points to 52,002.41. Market commentary said investors shifted from asking what AI can do to asking how it will be financed, hitting technology and growth stocks hardest.

The VIX rose 3.53 points to 19.99 after touching 22.31 intraday, its highest level since June 11.

Moderna's Intismeran Readout Looms

Rates remain a factor for biotech. The Federal Reserve's next decision is due October 28, after Fed Chair Kevin Warsh said, "I don't prejudge meetings." PCE inflation data follows on October 29, and the first estimate of third-quarter GDP is due the same day.

The Phase 3 intismeran data, expected later this month, is the key event for Moderna. The results will be closely watched by investors in both Moderna and Merck.